Back to top
more

United Therapeutics (UTHR)

(Delayed Data from NSDQ)

$355.93 USD

355.93
153,736

+5.86 (1.67%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $355.74 -0.19 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Nilanjan Choudhury headshot

5 Stocks in Focus on Remarkable Relative Price Strength

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

Nitish Marwah headshot

New Strong Buy Stocks for February 14th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.

Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod

Many biotech bigwigs came out with their fourth-quarter numbers in the past week.

Why United Therapeutics (UTHR) is Poised to Beat Earnings Estimates Again

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status

The FDA grants fast track status to Arena's (ARNA) early-stage candidate, APD418, for the treatment of decompensated heart failure.

Arena (ARNA) Expands Strategic Deal With Beacon Discovery

Arena (ARNA) enters into multi-year strategic partnership with Beacon Discovery to discover and develop therapies targeting multiple immune and inflammatory indications.

Arena Pharmaceuticals' (ARNA) Q3 Loss Widens, Revenues Beat

Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the third quarter of 2019 while revenues beat estimates.

United Therapeutics (UTHR) Q3 Earnings & Sales Top, Stock Up

United Therapeutics (UTHR) beats estimates on both fronts in the third quarter. Stock rises in response

Will United Therapeutics Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor United Therapeutics.

Zacks.com featured highlights include: Plexus, Costamare, United Therapeutics, Intel and First American Financial

Zacks.com featured highlights include: Plexus, Costamare, United Therapeutics, Intel and First American Financial

United Therapeutics (UTHR) Tops Q3 Earnings and Revenue Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 28.63% and 19.94%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) to Report Q3 Earnings: What's in the Cards?

Investors are looking forward to Cabometyx's performance and pipeline updates, when Exelixis (EXEL) reports Q3 results.

Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Nilanjan Choudhury headshot

5 Solid Relative Price Strength Stocks to Make You Rich

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?

Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

United Therapeutics' Trevyent NDA for PAH Accepted by FDA

United Therapeutics (UTHR) announces acceptance of Trevyent NDA by the FDA for pulmonary arterial hypertension.

Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?

Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet

Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the second quarter of 2019 while revenues are in line.

United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Down Y/Y

United Therapeutics (UTHR) beats estimates on both fronts in the second quarter. Loss of exclusivity for Adcirca and lower sales of Remodulin hurts sales.

United Therapeutics (UTHR) Q2 Earnings and Revenues Beat Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 51.25% and 12.60%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod

Arena (ARNA) doses first patient in one of the two pivotal late-stage studies evaluating its pipeline candidate, etrasimod in ulcerative colitis indication.

Arena Pharmaceuticals' (ARNA) Loss Widens in Q1 But Stock Up

Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics.

United Therapeutics (UTHR) Down Despite Q1 Earnings Beat

United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.

United Therapeutics (UTHR) Beats Q1 Earnings and Revenue Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 35.61% and 9.72%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?